Capmatinib (INC280) is an investigational, oral, potent and selective MET inhibitor licensed to Novartis by Incyte Corporation in 2009. Under the Agreement, Incyte granted Novartis worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications. Web相关研究建议,所有肺癌患者均应进行MET检测。好消息是,近年来,MET抑制剂的研究层出不穷,其中沃利替尼、Tepotinib和Capmatinib(卡马替尼,又名INC280)是已经获批的3款药物用于 MET 外显子 14 跳跃突变的转移性 NSCLC 治疗。
Phase I study of INC280 plus erlotinib in patients with MET …
WebJul 3, 2015 · Using in vitro and ex vivo models, we demonstrate that INC280 inhibits HGF-induced c-MET, and reduces downstream signalling. HGF-stimulated chemotactic and … WebDec 1, 2024 · INC280 was orally given at 3 mg/kg every day, whereas the INC280-PFCE NPs groups were administered a single 50 µL dose by IT instillation. The tumor volumes and body weights of the mice were monitored every two days. Tumor volumes were monitored by T1-weighted MRI. Survival was monitored to day 60 ( n = 8). cylch meithrin lle chi
Phase I study of INC280 plus erlotinib in patients with MET …
WebCapmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in … http://www.leirenbang.com/zx/2024/0408/245002.html WebAug 29, 2024 · Capmatinib (INC280) is a highly specific and potent MET inhibitor in biochemical and cellular assays that causes regression of MET-dependent (amplified/autocrine) tumors in animal models at well-tolerated doses. 8 Single-agent activity has been observed against EGFR wild-type tumor models with strong MET … cylch meithrin logo